Clinical Trials Logo

Clinical Trial Summary

Subjects received HPV 16 L1 VLP vaccine or placebo (1:1 ratio). Endpoints included efficacy, immunogenicity, and safety.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT00365378
Study type Interventional
Source Merck Sharp & Dohme Corp.
Contact
Status Completed
Phase Phase 2
Start date September 1999
Completion date July 2009

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06120205 - SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening N/A
Recruiting NCT06015854 - Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II Phase 2
Recruiting NCT05587725 - Human Papillomavirus in Young People Epidemiological Research 3
Recruiting NCT05587738 - Human Papillomavirus in Young People Epidemiological Research 4